The advent of bone growth factors has been widely anticipated since their s
uccessful production using recombinant DNA technology. Bone morphogenetic p
roteins (BMPs) are an im porta nt class of bone growth factors and will be
the focus of this article. In the near future these therapeutics might revo
lutionize how clinicians treat such diverse orthopedic applications as the
healing of broken bones, increasing bone density lost th rough aging, and s
trengthening the spine. These potent proteins require application directly
at the site of repair via a delivery system, The choice of delivery system
has a profound effect on the clinical outcome. In the past decade, research
ers have focused on developing efficient delivery systems and advancing the
se factors from the bench to the clinic.